Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...
Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam o ...
“Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, in late first-quarter/early second-quarter 2025.
VIENTIANE: The government plans to increase crop yields, upgrade processing plants, and expand the export market with a view ...
Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results